Orexin Peptides and Sleep-Wake Cycles

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Orexin peptides are key regulators of sleep and wakefulness, and their dysfunction is linked to sleep disorders like narcolepsy.

The Role of Orexins in Arousal and Wakefulness

Orexins, also known as hypocretins, are a pair of neuropeptides (orexin-A and orexin-B) that are produced by a small group of neurons in the lateral hypothalamus. These peptides are critical for the regulation of sleep-wake cycles, arousal, and appetite. Orexin-producing neurons project widely throughout the central nervous system, innervating various brain regions involved in wakefulness, including the locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), dorsal raphe nucleus (serotonin), and ventral tegmental area (dopamine) [1]. The tonic and phasic release of orexins promotes a state of sustained arousal and alertness, actively counteracting sleep-promoting signals. The orexin system is most active during the day, particularly during periods of high vigilance and motivation, helping to maintain a consolidated period of wakefulness and suppress REM sleep.

Mechanism of Action

Orexins exert their physiological effects by binding to two G protein-coupled receptors, the orexin receptor 1 (OX1R) and the orexin receptor 2 (OX2R). These receptors are expressed in numerous brain regions, reflecting the widespread influence of the orexin system [2]. Orexin-A (also known as hypocretin-1) binds to both OX1R and OX2R with high affinity, while orexin-B (hypocretin-2) binds preferentially to OX2R. The activation of these receptors leads to the depolarization of target neurons through the modulation of various ion channels and second messenger systems. This depolarization, in turn, enhances the release of several key wake-promoting neurotransmitters, such as norepinephrine, dopamine, serotonin, and histamine [3]. This intricate interplay positions the orexin system as a central hub, integrating signals from various parts of the brain—including those related to circadian rhythm, metabolic state, and emotional stimuli—to precisely regulate our level of arousal and maintain sleep-wake stability.

Orexins and Narcolepsy

The profound importance of the orexin system in sleep regulation is most dramatically highlighted by the debilitating sleep disorder narcolepsy type 1 (NT1), formerly known as narcolepsy with cataplexy. NT1 is characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by strong emotions), sleep paralysis, and hypnagogic/hypnopompic hallucinations [4]. It is now well-established that NT1 is caused by a selective and irreversible loss of approximately 90% of orexin-producing neurons in the hypothalamus [5]. This severe deficiency in orexin signaling leads to an inability to maintain a stable state of wakefulness, resulting in the characteristic symptoms of narcolepsy, including fragmented nocturnal sleep and involuntary transitions into REM sleep during wakefulness. The discovery of this causal link has revolutionized our understanding and treatment approaches for narcolepsy.

Therapeutic Targeting of the Orexin System

The discovery of the orexin system's pivotal role has opened up new avenues for the pharmacological treatment of sleep disorders.

Orexin Receptor Antagonists (DORAs) for Insomnia

Orexin receptor antagonists, particularly dual orexin receptor antagonists (DORAs), have been developed to treat insomnia. These drugs work by reversibly blocking the binding of endogenous orexins to both OX1R and OX2R, thereby suppressing wakefulness and promoting the natural onset and maintenance of sleep [6]. Unlike traditional hypnotics that often induce a "sedated" state, DORAs aim to facilitate a more physiological sleep architecture by dampening the hyperarousal often associated with insomnia.

Suvorexant (Belsomra): The first FDA-approved DORA, suvorexant, demonstrated efficacy in improving sleep onset and sleep maintenance in patients with insomnia [7]. Clinical trials showed significant improvements in subjective and objective sleep parameters.

Lemborexant (Dayvigo): Lemborexant is another DORA with a distinct pharmacokinetic profile, characterized by a rapid onset and appropriate duration of action, making it effective for both sleep onset and sleep maintenance insomnia [8]. Studies have shown its superiority over placebo and zolpidem in some measures.

  • Daridorexant (Quviviq): Daridorexant is the latest DORA to receive FDA approval. It is characterized by a targeted duration of action, aiming to provide sufficient sleep benefit without significant next-day residual effects. Clinical trials have demonstrated improvements in sleep onset, sleep maintenance, and subjective daytime functioning [9].

    • | Drug | Mechanism of Action | Indication | Key Features